• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

非达霉素在克服艰难梭菌感染中万古霉素治疗失败的作用：病例系列及文献综述

Fidaxomicin's Role in Overcoming Vancomycin Failure in Clostridium difficile Infections: A Case Series and Literature Review.

作者信息

Kloub Mohammad, Pati Shefali, Haddad Ahmad W, Abu Ruman Yazeed, Al-Maharmeh Qusai, Rayad Mohammad Nabil, Tewoldemedhin Bereket, Slim Jihad

机构信息

Department of Internal Medicine, Saint Michael's Medical Center, Newark, USA.

Department of Internal Medicine, St George's University, True Blue, GRD.

出版信息

Cureus. 2025 Mar 24;17(3):e81110. doi: 10.7759/cureus.81110. eCollection 2025 Mar.

DOI:10.7759/cureus.81110
PMID:40276451
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12018067/
Abstract

infection (CDI), characterized by diarrheal illness with serious complications, is a common pathology in clinical practice. We present a series of five patients with CDI who underwent treatment with fidaxomicin following the failure of oral vancomycin. To our knowledge, no evidence in the literature suggests that fidaxomicin is more effective than vancomycin in treating acute infection. This paper emphasizes the importance of utilizing a large study to determine the relative effectiveness of vancomycin versus fidaxomicin in treating CDI. We also provide a literature review on CDI and management evolution.

摘要

艰难梭菌感染（CDI）以伴有严重并发症的腹泻病为特征，是临床实践中一种常见的病理情况。我们报告了5例艰难梭菌感染患者，他们在口服万古霉素治疗失败后接受了非达霉素治疗。据我们所知，文献中没有证据表明非达霉素在治疗急性艰难梭菌感染方面比万古霉素更有效。本文强调了开展大型研究以确定万古霉素与非达霉素治疗艰难梭菌感染相对有效性的重要性。我们还提供了一篇关于艰难梭菌感染及其管理演变的文献综述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbb/12018067/235dbdb4dc69/cureus-0017-00000081110-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbb/12018067/a46125709705/cureus-0017-00000081110-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbb/12018067/d34ec734bf81/cureus-0017-00000081110-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbb/12018067/235dbdb4dc69/cureus-0017-00000081110-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbb/12018067/a46125709705/cureus-0017-00000081110-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbb/12018067/d34ec734bf81/cureus-0017-00000081110-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dbb/12018067/235dbdb4dc69/cureus-0017-00000081110-i03.jpg

相似文献

1
Fidaxomicin's Role in Overcoming Vancomycin Failure in Clostridium difficile Infections: A Case Series and Literature Review.非达霉素在克服艰难梭菌感染中万古霉素治疗失败的作用：病例系列及文献综述
Cureus. 2025 Mar 24;17(3):e81110. doi: 10.7759/cureus.81110. eCollection 2025 Mar.
2
Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.非达霉素：抗艰难梭菌感染的最新武器。
Clin Ther. 2012 Jan;34(1):1-13. doi: 10.1016/j.clinthera.2011.12.003.
3
Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.非达霉素与万古霉素治疗艰难梭菌感染初发 episode：一项荟萃分析与系统评价
Cureus. 2018 Jun 11;10(6):e2778. doi: 10.7759/cureus.2778.
4
Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant.对非达霉素与口服万古霉素治疗异基因干细胞移植中艰难梭菌感染的回顾性评估
Hematol Oncol Stem Cell Ther. 2018 Dec;11(4):233-240. doi: 10.1016/j.hemonc.2018.05.001. Epub 2018 Jun 18.
5
Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.成人艰难梭菌相关性腹泻的抗生素治疗
Cochrane Database Syst Rev. 2017 Mar 3;3(3):CD004610. doi: 10.1002/14651858.CD004610.pub5.
6
Fidaxomicin for the treatment of Clostridium difficile infections. fidaxomicin 治疗艰难梭菌感染。
Ann Pharmacother. 2012 Feb;46(2):219-28. doi: 10.1345/aph.1Q481. Epub 2012 Feb 7.
7
Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.非达霉素用于临床实践中艰难梭菌感染的治疗：法国一家大学医院的前瞻性队列研究
Infection. 2017 Aug;45(4):425-431. doi: 10.1007/s15010-017-0981-8. Epub 2017 Jan 24.
8
Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.西班牙对非达霉素治疗特殊人群（癌症患者、合并抗生素治疗患者或肾功能损害患者）艰难梭菌感染（CDI）的经济学评估。
Eur J Clin Microbiol Infect Dis. 2015 Nov;34(11):2213-23. doi: 10.1007/s10096-015-2472-0. Epub 2015 Sep 25.
9
SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.用于艰难梭菌感染（CDI）的SMT19969：在CDI仓鼠模型中与非达霉素和万古霉素相比的体内疗效
J Antimicrob Chemother. 2015;70(6):1757-62. doi: 10.1093/jac/dkv005. Epub 2015 Feb 3.
10
Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study. fidaxomicin 与口服万古霉素治疗严重艰难梭菌感染：回顾性队列研究。
Clin Microbiol Infect. 2019 Aug;25(8):987-993. doi: 10.1016/j.cmi.2018.12.007. Epub 2018 Dec 22.

本文引用的文献

1
Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials.口服 fidaxomicin 与万古霉素治疗艰难梭菌感染：系统评价和随机对照试验的荟萃分析。
J Infect Chemother. 2022 Nov;28(11):1536-1545. doi: 10.1016/j.jiac.2022.08.008. Epub 2022 Aug 11.
2
Characteristics, Risk Factors, and Prevalence of Among Hospitalized Patients in a Tertiary Care Hospital in Palestine.巴勒斯坦一家三级医疗医院住院患者的特征、风险因素及患病率。 （你提供的原文最后少了具体病症等关键信息，我按照完整的常见表述翻译了）
Infect Drug Resist. 2021 Nov 9;14:4681-4688. doi: 10.2147/IDR.S333985. eCollection 2021.
3
Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.
美国传染病学会 (IDSA) 和美国医疗保健流行病学学会 (SHEA) 的临床实践指南：2021 年关于成人艰难梭菌感染管理的重点更新指南。
Clin Infect Dis. 2021 Sep 7;73(5):e1029-e1044. doi: 10.1093/cid/ciab549.
4
Epidemiology of community-acquired and recurrent infection.社区获得性感染和复发性感染的流行病学
Therap Adv Gastroenterol. 2021 May 22;14:17562848211016248. doi: 10.1177/17562848211016248. eCollection 2021.
5
Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.艰难梭菌感染（CDI）负担 - 原发性和复发性 CDI 流行病学的系统评价。
BMC Infect Dis. 2021 May 19;21(1):456. doi: 10.1186/s12879-021-06147-y.
6
Clinical complications in patients with primary and recurrent infection: A real-world data analysis.原发性和复发性感染患者的临床并发症：一项真实世界数据分析。
SAGE Open Med. 2021 Jan 14;9:2050312120986733. doi: 10.1177/2050312120986733. eCollection 2021.
7
Infection: An Epidemiology Update.感染：流行病学最新进展
Clin Colon Rectal Surg. 2020 Mar;33(2):49-57. doi: 10.1055/s-0040-1701229. Epub 2020 Feb 25.
8
Regional differences in temporal incidence of Clostridium difficile infection: a systematic review and meta-analysis.区域间艰难梭菌感染时间发病差异：系统评价和荟萃分析。
Am J Infect Control. 2020 Jan;48(1):89-94. doi: 10.1016/j.ajic.2019.07.005. Epub 2019 Aug 3.
9
Recurrent Infection: Risk Factors, Treatment, and Prevention.反复感染：危险因素、治疗和预防。
Gut Liver. 2019 Jan 15;13(1):16-24. doi: 10.5009/gnl18071.
10
Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.非达霉素与万古霉素治疗艰难梭菌感染初发 episode：一项荟萃分析与系统评价
Cureus. 2018 Jun 11;10(6):e2778. doi: 10.7759/cureus.2778.